OrthoPediatrics (NASDAQ:KIDS) Price Target Increased to $42.00 by Analysts at Needham & Company LLC

OrthoPediatrics (NASDAQ:KIDS) had its target price hoisted by Needham & Company LLC from $37.00 to $42.00 in a report issued on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other research analysts have also issued reports about the stock. Truist Financial lowered shares of OrthoPediatrics from a buy rating to a hold rating and reduced their price target for the company from $39.00 to $31.00 in a research report on Thursday, January 25th. JMP Securities restated a market outperform rating and issued a $50.00 target price on shares of OrthoPediatrics in a research note on Tuesday.

OrthoPediatrics Stock Performance

Shares of KIDS opened at $34.70 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44. The stock has a market capitalization of $825.51 million, a price-to-earnings ratio of -37.72 and a beta of 1.16. OrthoPediatrics has a 52-week low of $23.10 and a 52-week high of $48.47. The stock’s 50-day simple moving average is $28.80 and its 200 day simple moving average is $29.04.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The firm had revenue of $37.61 million for the quarter, compared to the consensus estimate of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. Research analysts forecast that OrthoPediatrics will post -1.34 EPS for the current fiscal year.

Insider Activity

In related news, CEO David R. Bailey sold 3,213 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,646.67. Following the transaction, the chief executive officer now owns 139,384 shares of the company’s stock, valued at $3,845,604.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Mark C. Throdahl sold 2,433 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $67,126.47. Following the completion of the sale, the director now owns 137,857 shares of the company’s stock, valued at approximately $3,803,474.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David R. Bailey sold 3,213 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $88,646.67. Following the completion of the transaction, the chief executive officer now owns 139,384 shares in the company, valued at approximately $3,845,604.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,253 shares of company stock worth $477,375. 31.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Prime Capital Investment Advisors LLC bought a new position in OrthoPediatrics during the 4th quarter worth approximately $2,035,000. Vanguard Group Inc. raised its holdings in OrthoPediatrics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock valued at $27,546,000 after buying an additional 10,861 shares during the last quarter. Blue Trust Inc. boosted its position in OrthoPediatrics by 1.5% during the 4th quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock valued at $917,000 after buying an additional 421 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in OrthoPediatrics by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock worth $3,895,000 after acquiring an additional 549 shares during the last quarter. Finally, Conestoga Capital Advisors LLC increased its position in shares of OrthoPediatrics by 24.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after acquiring an additional 8,770 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.